What we're building
Live status of every TheraRadar feature. Updates as we ship. No vapor — items only move to "Up next" or "In progress" when we have a real start date.
Shipped
16Browse drugs by expedited pathway — Breakthrough, Fast Track, Orphan, Priority Review, Accelerated Approval — plus a filterable /approvals/ database.
Every upcoming FDA decision with context, month-by-month SEO pages, clickable company links, and an iCal feed you can subscribe to.
CBER biologics ingested from the Purple Book — Casgevy, Zolgensma, Carvykti, Kymriah and 300+ more — with modality, target, vector, and pricing breakdowns.
Start full-access Pro with no card required: exports, filters, alerts, watchlists, and every deep-analytics dashboard for 30 days.
Per-drug global patent families with expiry by country and editorial cliff commentary — for small molecules and biologics.
Pre-built mechanism-by-setting intelligence pages for crowded indications — Crohn’s, ulcerative colitis, Alzheimer’s, ALS, MS and more.
Global view of upcoming Phase 3 trial readouts across biotech, color-coded by urgency — same calendar style as PDUFA.
Long-form research on drugs, targets, and competitive dynamics, published at /briefs/ with email signup.
Hamburger nav, responsive grids, touch-friendly filter accordions across every page.
Pulse glyph favicon, Thera/Radar wordmark in teal, monochrome slate palette, updated OG image.
Approvals by year, modality breakdown, patent cliff timeline, route of administration, area × modality heatmap. PNG download.
Search 148,000+ trials with a competitive landscape bar showing exact percentages from precomputed slices.
Humira, Stelara, Revlimid, Tecfidera, Januvia, Lantus — actual SEC revenue declines, not Medicare proxies.
New hero, persona-first layout, brand-aligned visuals, public roadmap (this page), contact CTAs.
9 deep-analytics dashboards (Pipeline Health, Whitespace, Density, Landscape, Trends, Patent Cliff, Portfolios, Compare, Acquisition Watch) moved to Pro. Free tier keeps the 8 top-of-funnel dashboards (PDUFA, Trials Explorer, etc.).
Full rewrite with accurate feature inventory, yearly option ($990/yr, 2 months free), limited-time launch pricing, new comparison table, FAQ refresh.
In progress
0Nothing in progress right now.
Up next
3Side-by-side comparison of any two drugs — designations, clinical profile, indications, trial activity, patent expiry, and revenue.
Track how past PDUFA dates resolved — approved, CRL, or delayed — building a public track record and per-sponsor approval rates.
Expand mechanism-by-setting reports to hot oncology targets — KRAS G12C/G12D, Claudin 18.2, GPRC5D, DLL3, B7-H3, NECTIN-4 and more.
Planned
2Get notified when a watched drug enters a new trial phase or has a primary completion date approaching.
ML-derived probability of FDA approval for any Phase 3 drug, based on therapeutic area, modality, sponsor, biomarker, and trial design.
Have a feature you want?
We read every suggestion. The best ones end up in the "Up next" column above — usually within a sprint or two of the first mention.
Suggest a feature →Opens your email client with a short template. Or email [email protected] directly.
How this works
- Shipped — features that are live in production today. Click around the site to use them.
- In progress — actively being built. Usually ships within 1-2 weeks of appearing here.
- Up next — confirmed next workstream. Will move to "In progress" within the next sprint.
- Planned — committed to this quarter. Order may shift based on what users tell us matters most.